Mary de Groot1, David Marrero, Lisa Mele, Todd Doyle, Frank Schwartz, Kieren J Mather, Ronald Goldberg, David W Price, Yong Ma, William C Knowler. 1. From the Department of Medicine (de Groot, Mather), Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, University of Arizona School of Medicine (Marrero), Tucson, Arizona; Biostatistics Center (Mele, Ma), George Washington University, Rockville, Maryland; Department of Psychiatry and Behavioral Neurosciences (Doyle), Loyola University Medical Center, Maywood, Illinois; Camden Clark Memorial Hospital (Schwartz), Parkersburg, West Virginia; University of Miami School of Medicine (Goldberg), Miami, Florida; Department of Family Medicine (Price), University of Colorado Denver School of Medicine and Kaiser Permanente, Denver, Colorado; and National Institute of Diabetes and Digestive and Kidney Diseases (Knowler), Phoenix, Arizona.
Abstract
OBJECTIVE:Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). METHODS: DPP participants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). RESULTS: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7%) reported ADM use and 328 (10%) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20% higher, p = .01). Year 1 CRP decreased for non-ADM users in the MET (-13.2%) and ILS (-34%) groups and ADM users in the ILS group (-29%). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. CONCLUSIONS:ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.
RCT Entities:
OBJECTIVE: Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). METHODS:DPPparticipants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). RESULTS: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7%) reported ADM use and 328 (10%) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20% higher, p = .01). Year 1 CRP decreased for non-ADM users in the MET (-13.2%) and ILS (-34%) groups and ADM users in the ILS group (-29%). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. CONCLUSIONS: ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.
Authors: Wayne J Katon; Carolyn Rutter; Greg Simon; Elizabeth H B Lin; Evette Ludman; Paul Ciechanowski; Leslie Kinder; Bessie Young; Michael Von Korff Journal: Diabetes Care Date: 2005-11 Impact factor: 19.112
Authors: Richard R Rubin; Yong Ma; David G Marrero; Mark Peyrot; Elizabeth L Barrett-Connor; Steven E Kahn; Steven M Haffner; David W Price; William C Knowler Journal: Diabetes Care Date: 2007-12-10 Impact factor: 19.112
Authors: Aruna D Pradhan; Nancy R Cook; Julie E Buring; JoAnn E Manson; Paul M Ridker Journal: Arterioscler Thromb Vasc Biol Date: 2003-03-06 Impact factor: 8.311
Authors: Carol Kan; Kaushalya Jayaweera; Anushka Adikari; Sisira Siribaddana; Helena M S Zavos; Lisa Harber-Aschan; Athula Sumathipala; Matthew Hotopf; Khalida Ismail; Frühling Rijsdijk Journal: Psychosom Med Date: 2020 Feb/Mar Impact factor: 4.312